IRLAB Therapeutics AB

📍 Göteborg, Sweden🗓 Founded 2013👥 32 employees💰 Last funded May 2018
Biotechnology Research🌐 irlab.se
Website LinkedIn
IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's . In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam. IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB’s strong clinical pipeline, the company is also progressing two preclinical programs, IRL942 and IRL757, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2013
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in IRLAB Therapeutics AB?
IRLAB Therapeutics AB has 1 investors on record on gritt.io, 1 mid-stage.
When did IRLAB Therapeutics AB last raise funding?
The most recent investment in IRLAB Therapeutics AB recorded on gritt.io was in May 2018.
When was IRLAB Therapeutics AB founded?
IRLAB Therapeutics AB was founded in 2013.
What industry is IRLAB Therapeutics AB in?
IRLAB Therapeutics AB operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is IRLAB Therapeutics AB based?
IRLAB Therapeutics AB is headquartered in Göteborg, Sweden.